| abstract |
A therapy without interferon for the treatment of hepatitis C virus (HCV) is provided. In order to treat HCV genotype 1 infection, the treatment comprises administration of at least two direct acting antiviral agents (DAA) and ribavirin to an HCV patient, the treatment comprising administering interferon to the patient. Wherein the at least two DAAs comprise an HCV polymerase inhibitor and an HCV NS5A inhibitor, and the treatment lasts 8, 9, 10 or 11 weeks. The two DAAs comprise PSI-7777 and one of TMC-435, Daclatasville, GS-5858, or any combination of BM-790052 and BMS-650032, melicitabine and danoprevir or INX-189 and dacrasville. A method of treating HCV. [Selection] Figure 6C |